Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
about
Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP ChemotherapyCompatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.Improving Access to Cancer Treatments: The Role of Biosimilars.
P2860
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Study design: two long-term ob ...... motherapy-induced neutropenia.
@en
type
label
Study design: two long-term ob ...... motherapy-induced neutropenia.
@en
prefLabel
Study design: two long-term ob ...... motherapy-induced neutropenia.
@en
P2093
P2860
P356
P1433
P1476
Study design: two long-term ob ...... motherapy-induced neutropenia.
@en
P2093
Christian Berthou
Didier Kamioner
Fréderic Maloisel
Laurent Cals
Stefan Fruehauf
Stéphane Lepretre
P2860
P2888
P356
10.1186/1471-2407-13-547
P407
P577
2013-11-16T00:00:00Z
P5875
P6179
1016472332